Mayne Pharma Group Ltd (MYX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mayne Pharma Group Ltd (MYX) has a cash flow conversion efficiency ratio of 0.086x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$31.98 Million ≈ $22.63 Million USD) by net assets (AU$370.28 Million ≈ $262.00 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Mayne Pharma Group Ltd - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Mayne Pharma Group Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read MYX current and long-term liabilities for a breakdown of total debt and financial obligations.
Mayne Pharma Group Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mayne Pharma Group Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BICO Group AB
ST:BICO
|
-0.017x |
|
Clavister Holding AB (publ.)
ST:CLAV
|
-0.204x |
|
Kao Fong Machinery Co Ltd
TWO:4510
|
-0.009x |
|
Bank Capital Indonesia Tbk
JK:BACA
|
-0.012x |
|
Ilyang Pharmaceutical Co Ltd
KO:007575
|
0.009x |
|
UmweltBank AG
XETRA:UBK
|
-0.132x |
|
Muhak Co. Ltd
KO:033920
|
-0.009x |
|
Orogen Royalties Inc
V:OGN
|
0.015x |
Annual Cash Flow Conversion Efficiency for Mayne Pharma Group Ltd (2007–2025)
The table below shows the annual cash flow conversion efficiency of Mayne Pharma Group Ltd from 2007 to 2025. For the full company profile with market capitalisation and key ratios, see MYX market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$370.28 Million ≈ $262.00 Million |
AU$17.47 Million ≈ $12.36 Million |
0.047x | +240.05% |
| 2024-06-30 | AU$454.19 Million ≈ $321.37 Million |
AU$-15.30 Million ≈ $-10.83 Million |
-0.034x | +49.97% |
| 2023-06-30 | AU$634.36 Million ≈ $448.85 Million |
AU$-42.71 Million ≈ $-30.22 Million |
-0.067x | -420.56% |
| 2022-06-30 | AU$557.12 Million ≈ $394.20 Million |
AU$-7.21 Million ≈ $-5.10 Million |
-0.013x | -121.12% |
| 2021-06-30 | AU$771.58 Million ≈ $545.94 Million |
AU$47.26 Million ≈ $33.44 Million |
0.061x | -36.02% |
| 2020-06-30 | AU$1.04 Billion ≈ $737.50 Million |
AU$99.78 Million ≈ $70.60 Million |
0.096x | -8.94% |
| 2019-06-30 | AU$1.01 Billion ≈ $717.52 Million |
AU$106.61 Million ≈ $75.43 Million |
0.105x | +6.87% |
| 2018-06-30 | AU$1.24 Billion ≈ $873.95 Million |
AU$121.50 Million ≈ $85.97 Million |
0.098x | +947.27% |
| 2017-06-30 | AU$1.31 Billion ≈ $928.62 Million |
AU$-15.24 Million ≈ $-10.78 Million |
-0.012x | -108.16% |
| 2016-06-30 | AU$376.22 Million ≈ $266.20 Million |
AU$53.50 Million ≈ $37.86 Million |
0.142x | +104.38% |
| 2015-06-30 | AU$322.20 Million ≈ $227.98 Million |
AU$22.42 Million ≈ $15.86 Million |
0.070x | -57.60% |
| 2014-06-30 | AU$159.27 Million ≈ $112.70 Million |
AU$26.14 Million ≈ $18.49 Million |
0.164x | +189.81% |
| 2013-06-30 | AU$120.89 Million ≈ $85.54 Million |
AU$6.84 Million ≈ $4.84 Million |
0.057x | -87.06% |
| 2012-06-30 | AU$30.60 Million ≈ $21.65 Million |
AU$13.39 Million ≈ $9.47 Million |
0.437x | +158.83% |
| 2011-06-30 | AU$24.17 Million ≈ $17.10 Million |
AU$4.09 Million ≈ $2.89 Million |
0.169x | -57.89% |
| 2010-06-30 | AU$25.55 Million ≈ $18.08 Million |
AU$10.26 Million ≈ $7.26 Million |
0.401x | +186.15% |
| 2009-06-30 | AU$7.70 Million ≈ $5.45 Million |
AU$-3.59 Million ≈ $-2.54 Million |
-0.466x | -76.14% |
| 2008-06-30 | AU$11.44 Million ≈ $8.09 Million |
AU$-3.03 Million ≈ $-2.14 Million |
-0.265x | -209.97% |
| 2007-06-30 | AU$14.51 Million ≈ $10.27 Million |
AU$-1.24 Million ≈ $-876.47K |
-0.085x | -- |
About Mayne Pharma Group Ltd
Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract developmen… Read more